Sugi Predict

Sugi Predict / Compounds / SCHEMBL6609243

SCHEMBL6609243

SCHEMBL6609243

C=CCOC(=O)n1nnc(-c2ccc(F)cc2)c1-c1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 13/20 0.47
▸ MAPK13 O15264 3/20 0.40
▸ MAPK12 P53778 3/20 0.40
▸ MAPK11 Q15759 3/20 0.40
▸ CSNK1D P48730 3/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ MAPK9 P45984 2/20 0.38
▸ CSNK1A1 P48729 2/20 0.38
▸ CDC42BPA Q5VT25 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ MAP4K5 Q9Y4K4 1/20 0.38
▸ PRKD3 O94806 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ FRK P42685 1/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CSNK1G2 P78368 1/20 0.37
▸ PRKCD Q05655 1/20 0.37
▸ ERBB4 Q15303 1/20 0.37
▸ MINK1 Q8N4C8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640913 0.86 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6628431 0.82 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6771571 0.81 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6779785 0.77 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6622348 0.77 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6623836 0.77 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6614449 0.77 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6774189 0.74 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6768218 0.74 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL6688808 0.73 MGAM (0.50) MAPK14MAPK13MAPK12MAPK11CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 — — US claimed
EP-1383759-A1 TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY The Procter & Gamble Company (US) 2004-01-28 — — EP claimed
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 — — US claimed
WO-2002088108-A1 TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY THE PROCTER & GAMBLE COMPANY (US) 2002-11-07 — — WO claimed
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 MAPK14 3429/4885MAPK13 4097/4885MAPK12 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.